Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

EQS-News: Evotec SE: Launch of partnering agreement to strengthen biotech innovators in shared R&D economy
EQS-News: Evotec SE: Launch of partnering agreement to strengthen biotech innovators in shared R&D economy
EQS-News: Evotec SE: Launch of partnering agreement to strengthen biotech innovators in shared R&D economy
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
EQS-News: Evotec and Novo Nordisk launch LAB eN² to accelerate translation in cardiometabolic diseases
EQS-News: Evotec and Novo Nordisk launch LAB eN² to accelerate translation in cardiometabolic diseases
EQS-News: Evotec and Novo Nordisk launch LAB eN² to accelerate translation in cardiometabolic diseases
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Invitae Stock Analysis: Buy, Sell, or Hold?
Invitae Stock Analysis: Buy, Sell, or Hold?

Fool.com contributor Parkev Tatevosian considers Invitae (NYSE: NVTA) stock and its financial prospects to determine if investors should buy the stock.

*Stock prices used were the afternoon prices

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
2 Top Biotech Stocks Defying the Bear Market
2 Top Biotech Stocks Defying the Bear Market

Last year was challenging for the stock market. Things have been better since 2023 started, but some equities have even performed pretty well throughout this ordeal. That's the case with Exelixis

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Cathie Wood Is Betting on This Struggling Stock. Should You?
Cathie Wood Is Betting on This Struggling Stock. Should You?

Since December 2021, superstar investor Cathie Wood has been adding to her position in genetic-testing company Invitae (NYSE: NVTA) while many investors were doing just the opposite. The stock has

Want to Collect $500 in Dividends Every Month? Invest $90,000 in These 3 Stocks
Want to Collect $500 in Dividends Every Month? Invest $90,000 in These 3 Stocks

Inflation is giving investors more of an incentive to find ways to increase their income. If you have a decent nest egg saved up, you can use it to invest in dividend stocks to improve your

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
EQS-News: MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer
EQS-News: MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer
EQS-News: MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Why Shares of Neogen Are Slumping This Week
Why Shares of Neogen Are Slumping This Week

Shares of Neogen Corporation (NASDAQ: NEOG) were down more than 16% for the week, according to data provided by S&P Global Market Intelligence. The healthcare company, which specializes in food and

Why Insulet Stock Is Sinking Today
Why Insulet Stock Is Sinking Today

Shares of Insulet (NASDAQ: PODD) were sinking 9.3% as of 11:27 a.m. ET on Thursday after falling as much as 11.6% earlier in the session. The decline came as investors worried about the potential

EQS-News: SARTORIUS AG: Sartorius completes placement of bonds with a volume of 3 billion euros
EQS-News: SARTORIUS AG: Sartorius completes placement of bonds with a volume of 3 billion euros
EQS-News: SARTORIUS AG: Sartorius completes placement of bonds with a volume of 3 billion euros
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc